Advisory Services Network’s Allogene Therapeutics ALLO Stock Holding History

Advisory Services Network’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$361	Buy	+148	New	+$297	﹤0.01%	4476
2025 Q4	–	Sell	-4,069	Closed	-$5.05K	–	1880
2025 Q3	$5.05K	Buy	+4,069	New	+$4.85K	﹤0.01%	3537
2024 Q1	–	Sell	-960	Closed	-$3.08K	–	1516
2023 Q4	$3.08K	Buy	+960	New	+$2.72K	﹤0.01%	3275
2023 Q2	–	Sell	-148	Closed	-$731	–	1498
2023 Q1	$731	Hold	148	–	–	﹤0.01%	3668
2022 Q4	$931	Buy	+148	New	+$1.37K	﹤0.01%	3603
2021 Q3	–	Sell	-3,900	Closed	-$102K	–	1446
2021 Q2	$102K	Buy	+3,900	New	+$111K	﹤0.01%	1597
2020 Q4	–	Sell	-5	Closed	–	–	3272
2020 Q3	$0	Buy	+5	New	+$189	﹤0.01%	3532

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisory Services Network's ALLO Position: Q1 2026 in Review

Advisory Services Network opened a new position in Allogene Therapeutics (ALLO) in Q1 2026: 148 shares worth $361. The stake represents ﹤0.01% of the portfolio and ranks #4476 among its holdings. This is a return to the name: Advisory Services Network previously reported a position in ALLO as recently as Q3 2025.

Advisory Services Network first reported a position in ALLO in Q3 2020 and has held it in 7 quarters since. The position peaked at $102K in Q2 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

Advisory Services Network held 148 shares of Allogene Therapeutics worth $361 as of Q1 2026.
Allogene Therapeutics was a new Advisory Services Network position in Q1 2026.
Allogene Therapeutics made up ﹤0.01% of Advisory Services Network's portfolio in Q1 2026, its #4476 holding.
Advisory Services Network first reported a position in Allogene Therapeutics in Q3 2020 and has held it in 7 quarters since.
Advisory Services Network's Allogene Therapeutics position peaked at $102K in Q2 2021.
208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Advisory Services Network's 13F filing for Q1 2026, filed 15 May 2026.